R
René Adam
Researcher at Université Paris-Saclay
Publications - 634
Citations - 44864
René Adam is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 92, co-authored 578 publications receiving 37929 citations. Previous affiliations of René Adam include University of Padua & University of Paris.
Papers
More filters
Journal ArticleDOI
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
Thomas Gruenberger,John Bridgewater,Ian Chau,P. GarcÃa Alfonso,M. Rivoire,Satvinder Mudan,Susan F. Lasserre,F. Hermann,Daniel Waterkamp,René Adam +9 more
TL;DR: Bvacizumab-FOLFOXIRI was associated with higher response and resection rates and prolonged PFS versus bevac Zimab-mFOL FOX-6 in patients with initially unresectable liver metastases from colorectal cancer.
Journal ArticleDOI
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?
Bo Göran Ericzon,Henryk Wilczek,Marie Larsson,Priyantha Wijayatunga,Arie J. Stangou,J.R. Pena,Emanuel Furtado,Eduardo Barroso,Jorge Daniel,Didier Samuel,René Adam,Vincent Karam,John Poterucha,David Lewis,Ben Hur Ferraz-Neto,Márcia Waddington Cruz,Miguel Munar-Qués,Juan Fabregat,Shu Ichi Ikeda,Yukio Ando,Nigel Heaton,Gerd Otto,Ole B. Suhr +22 more
TL;DR: Long-term survival after Ltx, especially for early-onset TTR Val30Met patients, is excellent, and the risk of delaying Ltx by testing alternative treatments, especially in early-ONSet T transthyretin (TTR) amyloidosis patients, requires consideration.
Journal ArticleDOI
The Eurotransplant Donor Risk Index in Liver Transplantation : ET-DRI
Andries E. Braat,Joris J. Blok,Hein Putter,René Adam,A.K. Burroughs,Axel Rahmel,Robert J. Porte,Xavier Rogiers,Jan Ringers +8 more
TL;DR: Concordance‐index calculation shows this Eurotransplant Donor Risk Index to have high predictive value for outcome after liver transplantation, and advises the use of this ET‐DRI for risk indication and possibly for allocation purposes within the Eurotrans transplant region.
Journal ArticleDOI
OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer
Graeme J. Poston,René Adam,Steven R. Alberts,Steven A. Curley,Juan Figueras,Daniel G. Haller,Francis Kunstlinger,Gilles Mentha,Bernard Nordlinger,Yehuda Z. Patt,John N. Primrose,Mark S. Roh,Philippe Rougier,Theo J.M. Ruers,Hans-Joachim Schmoll,Carlos Valls,Nick Jean Nicolas Vauthey,Marleen Cornelis,James P. Kahan +18 more
TL;DR: A therapeutic decision model is created identifying individual patient resectability, recommending optimal treatment strategies and may also be used for medical education.
Journal ArticleDOI
Progression of Alphafetoprotein Before Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: A Critical Factor
Eric Vibert,Daniel Azoulay,Daniel Azoulay,Emir Hoti,S. Iacopinelli,Didier Samuel,Didier Samuel,C. Salloum,Antoinette Lemoine,Antoinette Lemoine,H. Bismuth,Denis Castaing,Denis Castaing,René Adam,René Adam +14 more
TL;DR: Increasing AFP >15 μg/L/month while waiting for LT is the most relevant preoperative prognostic factor for low OS/DFS.